Shares of Glenmark Pharmaceuticals Ltd were trading in the red and 1% lower on Thursday, 9 April, despite the company receiving final approval from the US Food and Drug Administration (USFDA) for its Progesterone Vaginal Inserts, 100 mg, increasing its portfolio in the women’s healthcare area.

The approved medicine is bioequivalent and medically equivalent to Ferring Pharmaceuticals’ reference drug, Endometrin Vaginal Inserts, the firm stated in an exchange filing.

Glenmark’s progesterone vaginal inserts will be distributed in the United States via its subsidiary, Glenmark Pharmaceuticals Inc.

According to IQVIA statistics, the Endometrin market generated annual sales of around $59.2 million in the 12 months ending February 2026, showing a moderate commercial opportunity.

Commenting on the development, Marc Kikuchi, President and Business Head, North America, said, “This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women’s healthcare.”

The product is commonly used in women’s healthcare, especially in fertility treatments. The approval adds to Glenmark’s increasing portfolio of US generics, as the company expands its foothold in regulated markets.

At 3:30 pm, the shares of Glenmark Pharma closed 0.71% lower at Rs 2,158.10 on NSE.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!